Back

New onset of left ventricular dysfunction and diastolic dysfunction are uncommon in patients with her2+ breast cancer after completion of cancer therapy.

31 August 2024 (13:00 - 13:50)
Organised by: Logo
Congress Presentation Part of: Caring for the patient with cancer and heart disease: the clinical perspective Cardio-Oncology ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Nichanan Osataphan

Chiang Mai University, Chiang Mai (Thailand)

7 More presentations in this session

Presentation thumbnail
Cardiovascular events and consequent risk of death in hematopoietic stem cell transplant recipients
Doctor G. Stronati (Ancona, IT)
Abstract Slides Video
Presentation thumbnail
Socioeconomic status and cardiovascular mortality in over 170,000 cancer survivors: a population-based cohort study
Doctor Y. Kim (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Routine application of cardiac magnetic resonance imaging in patients with suspected myocarditis from immune checkpoint inhibitor therapy
Mr T. Lerchner (Maastricht, NL)
Abstract Slides Video
Presentation thumbnail
Safety and effectiveness of sodium-glucose co-transporter 2 inhibitors in active cancer patients with heart failure: results of the observational TOSCA trial
Doctor M. Canale (Lido Di Camaiore, IT)
Abstract Slides Video
Presentation thumbnail
Cardiological monitoring during BTK inhibitor, ICI, and RAF/MEK inhibitor therapy: the single-center prospective registry for cardiovascular events under new cancer therapies (RECENT)
Doctor L. Seuthe (Cologne, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Caring for the patient with cancer and heart disease: the clinical perspective

The Event

Event poster

ESC Congress 2024

31 August 2024 13:00 CET
You may be interested in
thumbnail
Congress Presentation
Decoding chemotherapy-related cardiac dysfunction prediction: left ventricular strain imaging or HFA-ICOS score?
thumbnail
Congress Presentation
Evaluation of the predictive value of the HFA-ICOS score for cardiotoxicity in breast cancer patients treated with anthracyclines and trastuzumab: a real-world observational study
thumbnail
Congress Presentation
Longitudinal changes in right ventricular function in breast cancer patients undergoing cardiotoxic chemotherapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources